SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
SEC Accession No. 0001213900-24-010558
Filing Date
2024-02-06
Accepted
2024-02-06 16:15:16
Documents
1
Group Members
AISLING CAPITAL PARTNERS V LLCAISLING CAPITAL PARTNERS V, LPANDREW SCHIFFSTEVE ELMS

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO SCHEDULE 13G ea192928-13ga1aisling5_spru.htm SC 13G/A 97528
  Complete submission text file 0001213900-24-010558.txt   99258
Mailing Address 611 GATEWAY BOULEVARD, SUITE 740 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BOULEVARD, SUITE 740 SOUTH SAN FRANCISCO CA 94080 (415) 655-4168
SPRUCE BIOSCIENCES, INC. (Subject) CIK: 0001683553 (see all company filings)

IRS No.: 812154263 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-91764 | Film No.: 24600446
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 888 SEVENTH AVENUE, 12TH FLOOR NEW YORK NY 10106
Business Address 888 SEVENTH AVENUE, 12TH FLOOR NEW YORK NY 10106 212-651-6380
Aisling Capital V, LP (Filed by) CIK: 0001776233 (see all company filings)

IRS No.: 833267456 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A